Trump tariffs and changes at the FDA with David Lennarz

The president of Registrar Corp. discusses what Trump's tariffs might mean for US and international manufacturers and potential changes at the FDA under HHS Secretary Robert F. Kennedy Jr.
March 31, 2025
67e706a6c6d6fa6a5f6713a6 Lennarz Static Image

Key takeaways from this podcast:

  • Companies are breaking out the Covid playbook and shoring up relationships with alternative sources for goods 
  • Moving production to the US takes time and capital and may be out of reach for small and medium-sized companies
  • Many companies may turn away from the US toward growing Asian markets
  • Staffing cuts could impact FDA product reviews, approvals, and guidance documents 
  • FDA under RFK Jr. may move to simplify product labels, increase GRAS oversight and eliminate user fees

About the Author

Email

Nate Todd

Senior Editor

Sign up for our eNewsletters
Get the latest news and updates

Related

Basics of industrial tumble blenders for powders and bulk solids
Transforming shift handovers with digital reports
FactoryTalk PharmaSuite MES: Streamlining Batch Processing within the Life Sciences Industry
Sponsored